Evogene Ltd.
EVGN Healthcare Biotechnology
In the quarter to June 2026, revenue fell 35.0%, EPS grew 77.4% and free cash flow grew 17.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow EVGN
Evogene Ltd. (EVGN) EV/Sales
As of 16 October 2026, Evogene Ltd. (EVGN) trades at a EV/Sales of −2.8×. Over the past ten years it has ranged from −36.6× (March 2020) to 223× (February 2021); the current reading is higher than 18% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −1.1× | — |
| FY2024 | −0.8× | — |
| FY2023 | 1.6× | — |
| FY2022 | −3.1× | — |
| FY2021 | 13.4× | (83.46%) |
| FY2020 | 80.9× | — |
| FY2019 | −10.3× | — |
| FY2018 | −2.0× | — |
| FY2017 | 5.1× | (18.44%) |
| FY2016 | 6.3× | (29.74%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | −2.4× | — |
| Mar 2026 | −3.0× | — |
| Dec 2025 | −1.1× | — |
| Sep 2025 | −2.7× | — |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| EVGN Evogene Ltd. | −2.8× |
| ENVB Enveric Biosciences, Inc. compare | −0.1× |
| NRSN NeuroSense Therapeutics Ltd. compare | n/m |
| FBLG FibroBiologics Inc. compare | n/m |
| ALZN Alzamend Neuro, Inc. compare | n/m |
| ACXP Acurx Pharmaceuticals, Inc. compare | n/m |
| TRAW Traws Pharma, Inc. compare | 0.3× |
| LEXX Lexaria Bioscience Corp. compare | 2.4× |
| TCRT Alaunos Therapeutics, Inc. compare | 1,552× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)